Literature DB >> 12735117

Community-acquired pneumonia in elderly patients.

Michael S Niederman1, Qanta A A Ahmed.   

Abstract

CAP in elderly patients carries a significant economic and clinical burden and will be more commonly encountered in the future as the US population ages. Diagnosis may be obscured by a nonclassic presentation in an elderly patient, and the clinician needs to be especially suspicious of pneumonia whenever the clinical status of an elderly patient deteriorates. The single most important clinical decision is the site of care; this determination is not always based on clinical factors but also on social factors. Severity assessment is key to stratifying appropriate therapy and to predicting outcome. Timely and appropriate empiric therapy enhances the likelihood of a good clinical outcome, although clinical resolution may be more delayed than in younger patients. Newly emerging patterns of antibiotic resistance have altered recent guidelines for CAP treatment; DRSP is now a consideration in elderly patients because an age older than 65 years is a well-described risk factor for infection with this organism. Prevention should always be implemented, with a focus on pneumococcal and influenza vaccination.

Entities:  

Mesh:

Year:  2003        PMID: 12735117     DOI: 10.1016/s0749-0690(02)00061-7

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  7 in total

Review 1.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

2.  A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia.

Authors:  Tiemei Zhao; Liang-An Chen; Ping Wang; Guizhen Tian; Feng Ye; Huili Zhu; Bei He; Baiying Zhang; Changzhou Shao; Zhijun Jie; Xiwen Gao; Dongxia Wang; Weidong Song; Zhijie Pan; Jin Chen; Xingyi Zhang; Zhancheng Gao; Ping Chen; Youning Liu
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 3.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

Review 4.  Drug treatment of pneumococcal pneumonia in the elderly.

Authors:  Sridhar Neralla; Keith C Meyer
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 5.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).

Authors:  Anna M Ferrara
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

7.  A comparative study of clinical features and outcomes in young and older adults with severe acute respiratory syndrome.

Authors:  Tak Yeung Chan; Ka Ying Miu; Chung Kan Tsui; Kwok Sang Yee; Ming Houng Chan
Journal:  J Am Geriatr Soc       Date:  2004-08       Impact factor: 5.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.